Table 4.
Prognostic factors for progression-free survival (PFS) and overall survival (OS)
| Variable | 2-yearMFS | Log-Rank | 2-year PFS | Log-Rank | 2-year OS | Log-Rank |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male (n = 35) | 38.6% | p = 0.4 | 29.5% | p = 0.02 | 49.2% | p = 0.9 |
| Female (n = 11) | 55.1% | 11.3% | 45.7% | |||
| Histology | ||||||
| Squamous (n = 22) | 41.3% | p = 0.5 | 28.6% | p = 0.7 | 31.1% | p = 0.2 |
| Non squamous (n = 24) | 60.9% | 22.5% | 66.5% | |||
| Age | ||||||
| ≥ 66 years (n = 23) | 59.2% | p = 0.7 | 22.5% | p = 0.3 | 31.3% | p = 0.02 |
| < 66 years (n = 23) | 47.6% | 27.3% | 65.7% | |||
| Period between irradiations | ||||||
| > 24 months (n = 20) | 50.9% | p = 0.6 | 18.2% | p = 0.5 | 69.3% | p = 0.11 |
| ≤ 24 months (n = 25) | 55.6% | 33.4% | 37.9% | |||
| Missing value (n = 1) | ||||||
| > 12 months (n = 36) | 59.7% | p = 0.3 | 27.9% | p = 0.3 | 59.5% | p = 0.07 |
| ≤ 12 months (n = 9) | 21.4% | 18.8% | 12.7% | |||
| Missing value (n = 1) | ||||||
| Dose of reirradiation | ||||||
| BED ≤130 Gy (n = 18) | 61.1% | p = 0.15 | 28.3% | p = 0.2 | 47.9% | p = 0.8 |
| BED > 130 Gy (n = 28) | 44.4% | 23% | 49.6% | |||
| BEDmin ≤50 Gy (n = 21) | 53% | p = 0.3 | 21.2% | p = 0.7 | 52.9% | p = 0.4 |
| BEDmin > 50 Gy (n = 23) | 46.6% | 32.2% | 42.2% | |||
| SABR duration | ||||||
| ≥ 6 days (n = 25) | 51.9% | p = 0.3 | 21.6% | p = 0.3 | 53% | p = 0.6 |
| < 6 days (n = 20) | 54% | 30.3% | 45.2% | |||
| Number of fractions | ||||||
| > 3 (n = 30) | 50.7% | p = 0.5 | 17.5% | p = 0.4 | 47.1% | p = 0.6 |
| ≤ 3 (n = 16) | 56.6% | 40.8% | 52.1% | |||
| Dose per fraction | ||||||
| > 12 (n = 23) | 45.7% | p = 0.4 | 26.2% | p = 0.6 | 49% | p = 0.6 |
| ≤ 12 (n = 22) | 58.8% | 24.2% | 49.1% | |||
| Chemotherapy after reirradiation | ||||||
| Yes (n = 10) | 50.8% | p = 0.9 | 19% | p = 0.5 | 38.9% | p = 0.4 |
| No (n = 36) | 52.6% | 27% | 51.3% | |||
| Tumor size | ||||||
| ≥ 33 mm (n = 21) | 42.5% | p = 0.2 | 13.7% | p = 0.2 | 31.7% | p = 0.059 |
| < 33 mm (n = 22) | 58.9% | 31% | 69.8% | |||
| Missing value (n = 3) | ||||||
| GTV Volume | ||||||
| ≥ 13 mL (n = 22) | 38.4% | p = 0.12 | 13.1% | p = 0.10 | 27.3% | p = 0.06 |
| < 13 mL (n = 22) | 58.9% | 31% | 70.6% | |||
| Missing value (n = 2) | ||||||
| Performans Status - ECOGa | ||||||
| 0 (n = 27) | 57.4% | p = 0.3 | 34.2% | p = 0.6 | 59.9% | p = 0.4 |
| 1 (n = 11) | 60.6% | 21.8% | 66.3% | |||
| Missing value (n = 8) | ||||||
| Location of relapse | ||||||
| Central (n = 24) | 46.7% | p = 0.9 | 16.5% | p = 0.4 | 43.1% | p = 0.2 |
| Peripheral (n = 22) | 59% | 35.1% | 57.5% | |||
| Primary stage (at first irradiation) | ||||||
| IIIA (n = 21) | 59.7% | p = 0.3 | 30.6% | p = 0.3 | 49.2% | p = 0.3 |
| IIIB (n = 25) | 44.4% | 21.2% | 48.6% | |||
| In-field relapse | ||||||
| Yes (n = 29) | 47.4% | p = 0.4 | 18.3% | p = 0.11 | 42.4% | p = 0.11 |
| No (n = 17) | 58.8% | 37% | 61.1% | |||
| In-field and central tumors | ||||||
| Yes (n = 19) | 45.3% | p = 0.9 | 14.2% | p = 4 | 36.1% | p = 0.09 |
| No (n = 27) | 57% | 33% | 60.8% | |||
| Adjuvant chemotherapy | ||||||
| No (n = 36) | 52.6% | p = 0.8 | 27% | p = 0.5 | 51.3% | p = 0.4 |
| Yes (n = 10) | 50.8% | 19% | 38.9% | |||
| GTV coverage | ||||||
| < 95% (n = 22) | 48.9% | p = 0.8 | 19% | p = 0.6 | 47.2% | p = 0.7 |
| ≥ 95% (n = 24) | 54.4% | 33.3% | 49.9% | |||
| PTV coverage | ||||||
| < 90% (n = 23) | 46.6% | p = 0.9 | 18.2% | p = 0.5 | 44.9% | p = 0.9 |
| ≥ 90% (n = 23) | 58.1% | 35.6% | 52.4% | |||
aAt time of stereotactic ablative radiotherapy; ECOG = Eastern Cooperative Oncology Group